Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt